Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm

This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm. Blepharospasm is characterised by excessive contraction of the muscles around the eye and can lead to repetitive blinking or sustained closure of the eyelids.

Inclusion Criteria:

• Diagnosed with benign essential blepharospasm
• Received ≥20U/eye of BOTOX® for at least one visit prior to study entry and required, in the investigators opinion, the same dose at the study injection visit.
• Combined Jankovic Rating Score of >2

Exclusion Criteria:

• Female subjects who were pregnant, breastfeeding, or who were of childbirth potential and not practicing birth control.
• Profound atrophy of the muscles in the target area(s) of injection.
• Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis or any other disease that might interfere with neuromuscular function.
• Known significantly impaired renal and/or hepatic function